
APSL Biosimilar Portfolio

PIPELINE AT A GLANCE

AURIGENE
PHARMACEUTICAL SERVICES

- CELL LINE DEVELOPMENT
- PROCESS & ANALYTICS
- CLINICAL-READY
- COMMERCIAL SCALE-UP



UNDER DEVELOPMENT

9 early-stage assets

UP TO 5.4 g/L

- **Denosumab** Highest titer: 3.9 g/L
- **Dupilumab** Highest titer: 4.6 g/L
- **Atezolizumab** Highest titer: 4.6 g/L
- **Secukinumab** Highest titer: 5.4 g/L
- **Pertuzumab** Highest titer: 4.3 g/L
- **Ixekizumab** Highest titer: 3.5 g/L
- **Daratumumab** Highest titer: 5.4 g/L
- **Ustekinumab** Highest titer: 4.3 g/L
- **Ocrelizumab** Highest titer: 5.2 g/L

Status: CLD in progress / selected programs at stable pool or top clone stage.
All early-phase assets are amino acid sequence-confirmed against the innovator.

LATE-PHASE READY

4 priority assets

CTA-READY*

Pembrolizumab
anti-PD-1 | IV
Pilot CAA complete

Nivolumab
anti-PD-1 | IV
Pilot CAA, PC Phase I, PPQ, CAA complete

Tocilizumab
anti-IL-6R | IV + SC
Pilot CAA , PC complete. Phase I complete

Vedolizumab
anti-α4β7 | IV + SC
Pilot CAA, PC complete

Manufacturing status: clinical campaigns, PPQ, drug substance and drug product milestones completed or initiated.

CAA – Comparative Analytical Assessment; PC- Process Characterization; PPQ- Process Performance Qualification

CURRENT STATUS

- **4** Pilot CAA packages complete
- **2** IV & SC formulation platform
- **13** Assets across the portfolio